PrimeVigilance Augments Pharmacovigilance and Clinical Capabilities with Oracle Argus Collaboration

Guildford, UK, April 22, 2025

PrimeVigilance is Sole CRO to Achieve Oracle Lighthouse Status Partnership Ignites AI Across All Client Outcomes

As part of its continued efforts to optimize data management and analysis, boost efficiency, and ensure greater data accuracy and safety, PrimeVigilance, an Ergomed Group Limited company, is collaborating with Oracle Argus across pharmacovigilance, clinical, and other service areas. The Oracle Argus platform is recognized as the benchmark in processing, analyzing, and reporting adverse event cases, handling 10 million cases each year. Through this exclusive partnership, PrimeVigilance is the sole CRO to achieve Oracle Lighthouse status along with a software system that delivers a cost-effective cloud solution and enhanced performance.

 

Statement from Sally Amanuel, President of PrimeVigilance:

“The rise of chronic diseases and the increase in disease complexity is fueling increased AE volumes. Furthermore, the volume of data is set to explode with the rise of AI-enabled call centers agents, new sources of information like wearable technology and increasing regulations. The need to process ever larger volumes of data is driving increased demand for improved safety, monitoring, and risk mitigation strategies. This partnership with Oracle Argus allows us to integrate cutting-edge technologies, such as machine learning, natural language processing, and advanced data analytics, to enhance our case processing and scale our aggregate reporting capabilities. AI will process enormous amounts of incoming safety data, ensure compliance with evolving global regulatory frameworks, and effectively lower costs. Most importantly, it will empower our teams to shift their focus from repetitive or administrative tasks to more domain-specific knowledge and expertise for more sophisticated value-added activities thereby improving patient outcomes.”

 

In the age of synthetic datasets developed by regulators, PrimeVigilance believes that balancing technological and human power will decrease costs and increase efficiency. The company keeps track of scientific and technological trends, with a view to continually optimizing its internal ecosystem and embrace AI technologies, when they are acceptable by regulators. AI in the context of PrimeVigilance is more than algorithms.

 

PrimeVigilance’s clinical and post-marketing reporting capabilities are supported by Strategic Advisors, EU/UK Qualified Persons for Pharmacovigilance (QPPV) and local contact persons responsible for PV (LCPPV) who help set up and maintain complex global PV systems. Their expertise spans decades of industry experience, together with in-depth knowledge of industry trends and regulations.

 

 

 

About PrimeVigilance

PrimeVigilance, an Ergomed Group Limited company, is the leading pharmacovigilance specialist provider delivering global solutions for clinical safety and post-marketing pharmacovigilance and medical information from operational hubs based in Europe, the U.S., India, and Japan. Our extensive experience allows us to provide comprehensive, high-quality, cost-effective, and innovative safety solutions.

Our flexible, customized approach allows us to deliver services that align with client clinical and post-marketing needs. We provide pharmacovigilance solutions to 200+ clients who distribute their products worldwide and manage a comprehensive global pharmacovigilance system. For more information, visit www.primevigilance.com or contact info@primevigilance.com.